南昌市第十二医院治精神科专业么评价怎么样南昌如何正确治疗焦虑症,南昌第十二医院看精神科评价好嘛靠谱不,南昌焦虑如何治,神经官能症医院南昌那个好,南昌第十二医院精神科医院靠谱么评价怎样,南昌治抑郁症哪专业,南昌忧郁症有什么治疗办法

SAN DIEGO (KGTV) -- The Del Mar Thoroughbred Club has canceled its racing program this weekend, July 17-19. The cancellation follows 15 jockeys recently testing positive for COVID-19. Racing is slated to resume July 24."Assuming these individuals continue to show no symptoms, they will be isolated for a total of 10 days and should be able to resume their usual activities, including riding after that time,” said Dr. Eric McDonald, Medical Director, Epidemiology & Immunizations Services, County of San Diego.Racing at the track is set to return on July 24.The 15 jockeys who tested positive are believed to be asymptomatic, officials said. “Contact tracing procedures are underway in conjunction with the San Diego Health & Human Services Agency. However, a common factor among all but one of the riders that tested positive is that they rode at the recently concluded Los Alamitos meet.”The track ordered testing of all jockeys after two riders, Flavien Prat and Victor Espinoza, tested positive for COVID-19.Espinoza, who rode American Pharaoh to horse racing’s Triple Crown in 2015, spoke about his coronavirus diagnosis earlier this week on “The Winner’s Circle” podcast.Espinoza told podcast host Bram Weinstein that he took a COVID-19 test on July 7 and did not go to Del Mar’s opening weekend because he did not receive his results until July 10.The famed jockey described his symptoms as body aches and join pain, but he did not have a cough, fever or shortness of breath."It's different from a cold. Tuesday at 5 o'clock, it hit me hard for two hours. The next day I wake up normal like nothing happened. I feel fine ... The following day, my body starts hurting, every joint in my body, especially my legs, every joint from my hip to my ankles. And there's not much I can do, anything,” Espinoza told Weinstein.Espinoza added, "I've been in quarantine since March. I've been so careful to take care of myself, and it was one of those little things; you let your guard down, I went to Los Alamitos and that was it.”"Honestly, I can speak from my experience, I don't wish nobody to have this disease. Because, honestly, it's pretty bad,” Espinoza said.“Even though our jockey colony did not exhibit symptoms when they arrived at Del Mar, we made the decision to test everyone as part of protocols we have developed in conjunction with local medical experts and the San Diego County Health & Human Services Agency,” said Josh Rubinstein, Del Mar Thoroughbred President and COO. “We put these measures in place to help ensure the safety of all workers at Del Mar and our surrounding community.”Due to safety concerns, only jockeys based in California will be permitted to ride at Del Mar, the track said Wednesday. 2743

SAN DIEGO (KGTV) — The National Institutes of Health highlighted research Tuesday out of UC San Diego that could unlock a new way to treat COVID-19.The research reveals new insight into how the coronavirus hijacks cells, and how doctors might be able to set traps or decoys to combat the virus. The findings were published in the journal Cell last month.“It does open up another avenue for a potential treatment,” said UC San Diego distinguished professor Dr. Jeffrey Esko. “It’s not a cure. It would be something that would tamp down infection potentially.”Since January, scientists around the world have understood that SARS-Co-V2, the official name of the new coronavirus, enters cells by latching onto a specific receptor on the cell’s surface, called ACE2.The UCSD team, led by Dr. Esko and visiting scholar Dr. Thomas Clausen, discovered that this entry mechanism is actually a two-step process, and the virus must also attach to a long chain of sugars called heparan sulfate.“We’ve shown this is fundamental to the infectious mechanism, so it needs to be part of every study from now on,” said Clausen.All cells are coated with a complex layer of sugars, or carbohydrates, called glycans. Heparan sulfate is one type of glycan that is known to play a key role in the infection process in several viruses, including herpes and other coronaviruses.It’s a complicated process to picture so the researchers offer an analogy: imagine a bird, soaring over trees, hunting a worm on the forest floor. The bird is the coronavirus and the trees are the thick layer of glycans that coat the surface of the cell.To reach the worm, which in this case is the receptor ACE2, the bird must navigate its way through the trees, specifically through heparan sulfate.The UCSD found that by removing the heparan sulfate trees with an enzyme, they were able to prevent the virus from infecting cells. In laboratory testing, they also found a second technique worked to foil the virus: introducing more trees as bait.The team found that heparin, an FDA-approved drug that is similar in structure to heparan sulfate, successfully acted as decoy. Heparin is a widely used drug designed to treat blood clots. Since blood clots and strokes are common complications with COVID-19, many doctors already administer heparin to patients.The UCSD team demonstrated that the two approaches can block infection in lab-grown cells about 80 to 90 percent of the time.“Certainly in the laboratory you can demonstrate that it works, but to deploy it and use it as a therapeutic has not been demonstrated,” Esko said.The NIH noted that more studies are planned to explore whether heparin, heparan sulfate, or drugs that target heparan sulfate might yield a viable COVID-19 treatment.Dr. Esko said he’s already been in talks with companies that plan to use their study as a rationale for a clinical trial.“It is very humbling when you realize we’re working on a pandemic right now, and maybe what we’ve done can contribute to a treatment for the disease,” he said. 3038

SAN DIEGO (KGTV) — The Department of Defense has awarded a San Diego biotech company up to million to help develop a next-generation drug to fight COVID-19.Sorrento Therapeutics calls the drug a “rapid countermeasure” against the disease, one that might serve as a vaccine substitute in certain populations or a critical stopgap tool if the virus mutates.“With this, we have a new platform potentially that can respond very quickly to any type of emerging threat,” said CEO Dr. Henry Ji.Sorrento is trying to become the first company to develop an approved DNA-encoded monoclonal antibody treatment. The approach is similar to the experimental monoclonal antibody treatment used on President Trump, but Sorrento’s concept is a more advanced version that offers several benefits.Sorrento’s drug is designed to be used as either a treatment in infected patients or a fast-forming layer of defense in healthy people. The company said its solution should be cheaper and easier to deploy than existing monoclonal antibodies, while offering vaccine-like protective effects that last for several months rather than just two or three weeks.Antibodies are one of the body’s key defense mechanisms. They seek out pathogens and bind to them, marking the invader for destruction like ground troops marking an enemy base for an airstrike. In some cases, antibodies can even neutralize an invader themselves by blocking its method of entry into cells.Monoclonal antibodies are antibodies designed by scientists to neutralize a pathogen. They are hand-picked, genetically modified super antibodies that are cloned in labs.However, the process of growing these super soldiers in the lab is difficult, transporting them requires a cold chain, and as a result, monoclonal antibodies are among the most expensive drugs in the world.Instead of giving people an infusion of pre-made antibodies, Sorrento’s idea is to give people a shot of DNA that instructs some of their cells to churn out perfectly pre-designed antibodies.“It's much easier to make enough DNA to treat a large number of people than it is to make enough protein to treat a large number of people. That’s just a fact about manufacturing,” said Dr. Robert Allen, Sorrento’s chief scientific officer on the project.Dr. Allen said the company is hopeful the drug will induce cells to make protective antibodies for six months or more.This DNA approach to an antibody treatment has never been approved for any disease but other companies are working on their own versions of it. Another biotech with ties to San Diego, Inovio Pharmaceuticals, became the first company to test this approach in humans in 2019 for a drug targeting the Zika virus.Sorrento’s approach is similar to the way DNA vaccines work, but it cuts out intermediary steps and jumpstarts the production of antibodies, rather than leaving the production of antibodies up to the body’s immune system. The result is that protective antibodies can start circulating in days after injection rather than weeks, the company said.“What this is capable of doing is it bypasses the need for the immune system,” said Dr. Mark Brunswick, Sorrento’s senior vice president for regulatory affairs.The drug is unlikely to replace a vaccine in most situations because vaccines can produce other defense mechanisms like T-cells that work in conjunction with antibodies. But the drug might work better than a vaccine for the elderly and others with weakened immune systems who are unable to produce a robust number of antibodies on their own, Brunswick said.Still, the company still has a lot of pre-clinical work and testing to go. Sorrento is hoping to have the drug ready for human trials in four to six months.By then, vaccines from Pfizer and Moderna will likely be widely available, but Dr. Ji said the world needs to prepare for the possibility this virus will mutate.“When you vaccinate hundreds of millions, potentially billions of people, the virus is under tremendous evolution pressure,” he said. “It will escape. It’s guaranteed that the virus is going to mutate and escape all of the vaccines we’re trying to create.”If it does, he said Sorrento will be ready to rapidly deploy its DNA-based countermeasure. 4223

SAN DIEGO (KGTV) - The autopsy of the driver who drove up an off-ramp the wrong way onto the 805 and slammed into an SUV holding a mother and her 12-year-old daughter was released Friday.READ RELATED:?Autopsy details mental state of McSkillet before deadly crash on Interstate 805 in San DiegoThe report states the death of Trevor Heitmann, 18, also known on YouTube as McSkillet, was accidental and he had no drugs or alcohol in his system during the time of the crash."I'm not doing good and bad is an understatement," Dominic Pizarro, 22, says the past two months has been a challenge each day.He lost his mother, Aileen Pizarro, 43, and sister, Aryana."It's interesting the fact he had nothing in his system, and I think it's much sadder in that aspect," Pizarro said at first read, the report angered him. Then, as he understood the context, his frustration disintegrated, concerned more with the fact Heitmann never got help. "I feel for the family in that case. He, you know, nobody should have to go through that."That, referring to the loss of someone integrated into the fabric of your daily life, "I would always try to go and make a phone call to mom about how my day went, which is what I would do when I was away at training for the Air Force. I would call my family and let them know how my day is going, and that took a while to learn I can't do that anymore," he said. Throughout the interview, he was strong and stable, never shying away from a question or getting emotional.He said each day he fights a battle, whether it's just getting up in the morning, or something reminding him in the middle of his day that they're never coming back.He is back at school, studying for his Master's Degree, and taking what happened to him as a way to give back, "we're trying to do a scholarship in my sister's honor for musicians."The Aryana Pizarro Music Scholarship will help talented kids, like his sister, get the funding they need to perfect their art.Dominic said because of his deep faith, friends, and family, he's been able to push forward. He hopes others can find peace in the faith he's grown."I think people easily either choose like you said to do something selfish or to give up and I don't want people to give up, I, I, giving up is too easy... [surviving] is worth it." 2352

SAN DIEGO (KGTV) - The city updated the Sherman Heights community and surrounding neighborhoods Wednesday evening, about the transitional homeless storage facility that's set to open.  The facility is scheduled to open at the corner of the Commerical and 20th Streets on June 13.  It's been a controversial project from the beginning. The storage facility will hold 500 units for homeless people to store their things while they look for work and get back on their feet.  RELATED:  514